{"id":7255,"date":"2026-06-14T12:34:24","date_gmt":"2026-06-14T12:34:24","guid":{"rendered":"https:\/\/www.fintechpulse8.com\/?p=7255"},"modified":"2026-06-14T12:34:24","modified_gmt":"2026-06-14T12:34:24","slug":"goldman-sachs-doubles-down-on-novo-stock-target-after-key-event","status":"publish","type":"post","link":"https:\/\/www.fintechpulse8.com\/?p=7255","title":{"rendered":"Goldman Sachs doubles down on Novo stock target after key event"},"content":{"rendered":"<p><\/p>\n<p>Novo Nordisk (NVO) has spent 2026 trying to convince investors that the worst is behind it.<\/p>\n<p>After a punishing year, the stock is finally clawing back from its lows.<\/p>\n<p>So, when Goldman Sachs sat down with management at a major healthcare conference this month, investors wondered if the bank would turn more positive about Novo\u2019s stock.<\/p>\n<p>The answer was clear: <\/p>\n<p><strong>Goldman left its rating and target right where they were<\/strong>, indicating where the GLP-1 race stands today.<\/p>\n<h2>What Goldman Sachs decided on Novo Nordisk stock after the conference<\/h2>\n<p>Goldman Sachs reaffirmed its Neutral rating and $47 price target on Novo Nordisk stock after meeting management at the 47th Annual Global Healthcare Conference on June 9.<\/p>\n<p>The bank had lifted that target to $47 from $41 on June 3, so the conference note effectively cemented its stance, according to TipRanks data.<\/p>\n<p><strong>More Pharma Stocks:<\/strong><\/p>\n<ul>\n<li><strong>Banking giant massively resets Jazz Pharma stock price target<\/strong><\/li>\n<li><strong>Eli Lilly scores a first in major pharma milestone<\/strong><\/li>\n<li><strong>Eli Lilly makes surprising retreat from major market<\/strong><\/li>\n<\/ul>\n<p>The $47 figure sits about 7% above where the shares are trading at the time of writing, closing June 12 at 287.25 Danish kroner, up 1.66% on the day and about 2.9% over five sessions.<\/p>\n<figure>\n<p>                        <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.thestreet.com\/.image\/NDA6MDAwMDAwMDAzMDc4MDM5\/novologo_pl_130626.jpg?profile=rss\" height=\"675\" width=\"1013\"><figcaption>Novo Nordisk\u2019s Wegovy franchise sits at the center of Goldman Sachs\u2019s $47 price target call.<\/p>\n<p>NurPhoto &amp;sol; Getty Images<\/p>\n<\/figcaption><\/figure>\n<h2>Why Novo Nordisk stock fell so far before this rebound<\/h2>\n<p>To see why a $47 target counts as progress, you have to remember how brutal the drop was.<\/p>\n<p>Novo shares hit a 52-week low near $37 earlier this year, down from a high above $90, after its next-generation obesity drug CagriSema missed a key trial goal in February, TIKR reported.<\/p>\n<p>The company then guided to a full-year sales decline and announced a restructuring that cut roughly 9,000 jobs.<\/p>\n<p>It also kept losing ground to Eli Lilly, which held about 60% of the combined U.S. obesity and diabetes GLP-1 market in the first quarter against Novo\u2019s 39%.<\/p>\n<h2>What the Wegovy pill and Ozempic could mean for Novo\u2019s recovery<\/h2>\n<p>The most useful detail from the conference was about the market demand for the Wegovy pill.<\/p>\n<p>Goldman said most users are people who have never taken a GLP-1 drug before, which means the pill is growing the market, not just relying on existing patients alone.<\/p>\n<p align=\"center\"><strong>Related: Wall Street sees huge upside as Novo Nordisk backs biotech company<\/strong><\/p>\n<p>Novo also has Wegovy HD, a higher-strength 7.2 mg injection cleared by the FDA in March that can drive weight loss of about 21%, as disclosed in the company\u2019s SEC filing.<\/p>\n<p>That gives doctors a stronger dosing option and a reason to keep prescribing Wegovy.<\/p>\n<p>On diabetes, Novo is leaning on the trusted Ozempic name as it rolls out an Ozempic pill in the U.S., with approval for a higher dose expected later this year.<\/p>\n<h2>How Medicare could slowly reshape Novo Nordisk\u2019s sales<\/h2>\n<p>A big swing factor is Medicare.<\/p>\n<p>The Centers for Medicare &amp; Medicaid Services launched a GLP-1 Bridge program that opens coverage to qualified Part D members from July 1.<\/p>\n<p>Novo believes about 20 million Medicare patients could qualify for obesity treatment over time.<\/p>\n<p>The catch is speed:<\/p>\n<p>Novo expects a steady ramp, not a sudden surge, due to appointment backlogs and the hurdles insurers and pharmacy benefit managers impose to control which drugs are filled.<\/p>\n<p>For investors, that means <strong>Medicare is a slow tailwind<\/strong>, not an instant revenue jump.<\/p>\n<h2>What still has to happen for Novo Nordisk stock to climb<\/h2>\n<p>Goldman\u2019s cautious stance comes down to execution. The pieces are in place, but the bank wants proof before it gets more bullish.<\/p>\n<h3>What to watch next on Novo Nordisk stock<\/h3>\n<ul>\n<li><strong>Whether Wegovy pill demand holds up <\/strong>as Novo launches in more countries by year end.<\/li>\n<li><strong>How fast the Ozempic pill gains traction<\/strong>, plus that higher-dose approval.<\/li>\n<li><strong>Whether Medicare sales build slowly<\/strong>, as Novo expects, or ramp up faster.<\/li>\n<li><strong>Lilly\u2019s pressure from its Foundayo pill<\/strong> and an early direct-to-consumer ad push.<\/li>\n<\/ul>\n<p>The clearest risk is competition. <\/p>\n<p>Lilly continues to win payer coverage and share, and\u00a0Bank of America remains bullish after a strong quarter.<\/p>\n<h2>The bottom line for Novo Nordisk investors<\/h2>\n<p>Goldman\u2019s message is that the recovery looks real but still has to be earned.<\/p>\n<p>The Street remains split, with the average analyst target sitting near $47, according to Stock Analysis, close to where Goldman landed.<\/p>\n<p>For now, the stock is regaining some ground, and a Neutral rating with modest implied gains is a fair reflection of that. <\/p>\n<p>If you\u2019re thinking of investing, you can watch for clear evidence that the Wegovy pill, Ozempic, and Medicare can deliver before paying up for Novo Nordisk again.<\/p>\n<p align=\"center\"><strong>Related: 245-year-old pharma giant cuts 4,500 jobs amid legal troubles<\/strong><\/p>\n<p>#Goldman #Sachs #doubles #Novo #stock #target #key #event<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NVO) has spent 2026 trying to convince investors that the worst is behind it. After a punishing year, the stock is finally clawing back from its lows. So,&hellip; <\/p>\n","protected":false},"author":1,"featured_media":7256,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[246],"tags":[2390,4858,1360,510,4913,1361,91,1196],"class_list":["post-7255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-popular","tag-doubles","tag-event","tag-goldman","tag-key","tag-novo","tag-sachs","tag-stock","tag-target"],"_links":{"self":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/7255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7255"}],"version-history":[{"count":0,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/7255\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/media\/7256"}],"wp:attachment":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}